Dabigatran therapy did not result in a reduction of recurrent strokes compared to aspirin use after embolic stroke of undetermined source, whereas nonmajor bleeding was higher with dabigatran.
A meta-analysis showed significantly elevated Lp(a) levels with statin therapy and a cell culture study demonstrated increased apo(a) production after statin treatment, which possibly contributes to the residual CV risk in subjects on statins.
Subodh Verma gives a presentation focusing on various proposed mechanisms through which SGLT2 inhibition can result in a reduction of CV events and HF outcomes.
ADA 2019 Oral formulation of GLP-1RA semaglutide was not inferior to placebo with regard to major adverse cardiac events in T2DM patients with high CV risk.
ADA 2019 Results of the CAROLINA trial showed similar CV effects of the DPP-4 inhibitor linagliptin vs. the sulfonylurea glimepiride in T2DM patients with CVD or high CV risk.
ADA 2019 In a subanalysis of the DECLARE-TIMI 58 trial, patients with T2DM showed reduced progression of kidney disease and fewer renal events when treated with dapagliflozin vs placebo.
ADA 2019 The REWIND trial, which included a majority of participants without established CVD, showed that dulaglutide treatment resulted in 12% reduction in MACE, irrespective of history of CVD.
A single-center prospective PCI-registry showed an independent association of high residual inflammatory risk and adverse clinical outcomes in patients undergoing PCI with LDL-c ≤70 mg/dL at baseline.
9% Of adults who experience MI before 50 years of age, have probable or definite FH. Statin therapy is often suboptimal and so are LDL-c levels at 1 year post-MI.
EAS 2019 Professor Nordestgaard notes that the importance of remnant cholesterol is increasingly recognized, as it is causally related to risk of ischemic stroke, myocardial infarction and all-cause mortality.
The exploratory ELIMINATE-AF study demonstrated that uninterrupted treatment with edoxaban represents an alternative to continuous VKA in patients undergoing catheter ablation of AF.
EAS 2019 By debating on whether high Lp(a) levels should be treated or not, Brian Ference and Sotirios Tsimikas critically reviewed the available evidence on the link between Lp(a) and CV risk. With poll